Next Article in Journal
A General Strategy for the Preparation of Carbon Nanotubes and Graphene Oxide Decorated with PdO Nanoparticles in Water
Next Article in Special Issue
Inhibition of HIV-1 Replication and Dimerization Interference by Dual Inhibitory RNAs
Previous Article in Journal
Supported and Non-Supported Ruthenium(II)/Phosphine/[3-(2-Aminoethyl)aminopropyl]trimethoxysilane Complexes and Their Activities in the Chemoselective Hydrogenation of trans-4-Phenyl-3-butene-2-al
Previous Article in Special Issue
In Vitro and Ex Vivo Selection Procedures for Identifying Potentially Therapeutic DNA and RNA Molecules
Article Menu

Article Versions

Export Article

Open AccessReview
Molecules 2010, 15(7), 4670-4678;

Ribozyme-Mediated Inhibition of 801-bp Deletion-Mutant Epidermal Growth Factor Receptor mRNA Expression in Glioblastoma Multiforme

Department of Neurosurgery, University of Ulm Medical School, Steinhövelstr 9, D-89075 Ulm, Germany
Author to whom correspondence should be addressed.
Received: 8 June 2010 / Revised: 28 June 2010 / Accepted: 29 June 2010 / Published: 30 June 2010
(This article belongs to the Special Issue Catalytic Nucleic Acids)
PDF [234 KB, uploaded 18 June 2014]


The epidermal growth factor receptor (HER1/EGFR) is known to be disregulated in a large subgroup of glioblastoma multiforme cases. Disregulation of HER1/EGFR is related to malignant transformation and tumor growth in various human cancers, including malignant glioma. One mechanism that may lead to disregulated HER1/EGFR signaling is the intrinsic alteration of the receptor structure due to mutational changes. The most common mutant form of HER1/EGFR, named variant III (EGFRvIII), results from an 801 bp in-frame deletion in the DNA sequence encoding the extracellular ligand-binding domain. Independent of ligand–binding, EGFRvIII is constitutively activated and beyond external control. Since its cellular expression was shown to relate enhanced tumorigenicity, various therapeutic strategies were developed to target EGFRvIII, including monoclonal antibodies, vaccination therapies and small-molecule tyrosine kinase inhibitors. In this review, we focus on ribozyme-mediated inhibition of EGFRvIII messenger RNA expression as a gene therapeutic approach for EGFRvIII-expressing glioblastoma multiforme.
Keywords: EGFRvIII; ribozymes; retrovirus-mediated DNA transfer EGFRvIII; ribozymes; retrovirus-mediated DNA transfer
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Karpel-Massler, G.; Wirtz, C.R.; Halatsch, M.-E. Ribozyme-Mediated Inhibition of 801-bp Deletion-Mutant Epidermal Growth Factor Receptor mRNA Expression in Glioblastoma Multiforme. Molecules 2010, 15, 4670-4678.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top